Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TM38837 and rimonabant crossover challenge study with inhaled THC in healthy male volunteers
NL-OMON32430Active, not recruiting
- Sponsor
- 7TM Pharma
- Start
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in obesity comparing TM38837 + THC, rimonabant + THC and placebo + THC (3 arms). Primary endpoint: Effect of TM38837 on THC-induced central effects. Started Mar 2010; status: active, not recruiting.
02
Drugs
TM38837rimonabantdronabinol
03
Conditions
obesity
Beyond the preview
Go deeper on NL-OMON32430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32430.